Jump to content
An amber-phosphor terminal readout of the TB-500 record — every finding, dose range, and caveat dumped to the console.
MD/TB-500

About MD/TB-500: A Terminal Readout of the TB-500 Research | MD/TB-500

About This Console

MD/TB-500 dumps the peer-reviewed research on TB-500 and its parent compound thymosin beta-4 to a terminal readout — the whole record printed out, tagged, and cited. No clinic runs here and no clinical staff stand behind it; it hands out no medical advice; it makes, stocks, and ships nothing. What prints to the screen is the record and the holes in it, never a treatment.

The TB-500 research record is a technically dense literature built on top of a well-characterized molecular mechanism — G-actin sequestration, ILK/PINCH/Akt signaling, NF-kB inhibition — with a genuine clinical translation gap between the preclinical findings and the absence of human heptapeptide trials. That gap is not a reason to ignore the literature; it is a reason to read it carefully, classify each finding by evidence class, and be precise about what has and has not been shown.

This site uses the amber-CRT terminal register deliberately. The 'MD' in MD/TB-500 is not a medical degree. It is a machine dump: the complete TB-500 and thymosin beta-4 research record rendered to stdout in the format a research console would produce. Every finding is tagged by evidence class. Every quantitative claim is cited. The WADA prohibition status is displayed in the header readout in red, because it is a real regulatory fact about this compound.

The domain name does not imply clinical services. MD/TB-500 is not affiliated with any clinical practice, compounding pharmacy, telemedicine provider, or peptide vendor. No healthcare professionals are employed by or associated with this publication.

What We Publish

MD/TB-500 publishes research summaries covering:

  • Mechanism of action: G-actin sequestration, ILK/Akt pathway, NF-kB inhibition, VEGF modulation
  • Tissue repair studies: ligament, dermal wound, corneal, bone, and cardiac preclinical data
  • Dosage context from the preclinical and equine literature
  • Adverse event and safety data from animal studies and full-length thymosin beta-4 human Phase 1-2 trials
  • Anti-doping status and regulatory context
  • Comparison with related research peptides including BPC-157
  • Hair follicle research

Every quantitative claim on this site is sourced from a peer-reviewed publication indexed in PubMed, PMC, or a peer-reviewed journal archive. No claims originate from forum posts, anecdotal reports, manufacturer materials, or gray literature. The TB-500 mechanism of action page documents the molecular pathways in detail.

This site covers TB-500 and its parent protein thymosin beta-4 as research subjects. We do not cover clinical treatment, dosing recommendations, or procurement sources.

Editorial Independence

MD/TB-500 has no commercial relationship with any peptide vendor, compounding pharmacy, telemedicine provider, laboratory supplier, or clinical practice. The site does not carry affiliate links to peptide vendors. The site does not sell any product or service.

Research summaries are written by editorial staff with backgrounds in scientific literature review. Summaries are sourced from primary literature — original research articles and systematic reviews — not from secondary commentary or industry white papers. Every citation is linked to its PubMed or PMC record where publicly accessible.

The editorial position on TB-500 is: the preclinical mechanistic record is solid, the tissue-repair findings are reproducible across multiple models, and the clinical translation gap (no published human trial of the heptapeptide) is real and should be explicitly stated rather than papered over. The 2024 metabolite finding (that Ac-LKKTE rather than the parent Ac-LKKTETQ may be the active species) is cited and discussed because it is part of the honest record.